Acrivon Therapeutics, Inc. Common Stock (ACRV) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Peter Blume-Jensen	Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer	1.13M	1963
Erick Gamelin	Chief Development Officer	480,723	1958
Mary-Alice Miller	Chief Legal Officer & Corporate Secretary	587,108	1974
Eric J. Devroe	Chief Operating Officer	784,797	1979
Kristina Masson	Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer & Director	851,720	1980
Adam D. Levy	Chief Financial Officer & Principal Financial Officer	0	1966
Jesper V. Olsen	Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board	0	N/A
Bruce Close	Vice President of Quality & Compliance	0	N/A
Joon Jung	Vice President & Head of Data Science	0	N/A
Katharine Peterson	Vice President of Finance & Accounting	0	N/A

Name

Title

Pay

Year Born

Peter Blume-Jensen

Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer

1.13M

1963

Erick Gamelin

Chief Development Officer

480,723

1958

Mary-Alice Miller

Chief Legal Officer & Corporate Secretary

587,108

1974

Eric J. Devroe

Chief Operating Officer

784,797

1979

Kristina Masson

Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer & Director

851,720

1980

Adam D. Levy

Chief Financial Officer & Principal Financial Officer

1966

Jesper V. Olsen

Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board

N/A

Bruce Close

Vice President of Quality & Compliance

N/A

Joon Jung

Vice President & Head of Data Science

N/A

Katharine Peterson

Vice President of Finance & Accounting

N/A

Description

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.